The Food and Drug Administration approved Syndros, a cannaboid dronabinol oral solution created by Phoenix-based Insys Therapeutics.
Syndros was approved for two indications — to treat anorexia associated with weight loss in patients with AIDS and to relieve nausea and vomiting caused by chemotherapy for cancer patients who do not respond to conventional antiemetic treatments.
"Syndros is the first and only FDA approved dronabinol solution for oral use. It is a liquid that is easy-to-swallow and allows for the dosage to be titrated to clinical effect. Once Syndros has been opened, it does not need to be refrigerated for 28 days," said John N. Kapoor, MD, CEO and president of Insys Therapeutics.
The company expects to launch Syndros in late 2016.
More articles on the drug market:
Astrazeneca sells 2 drug rights to LEO Pharma
Drugmakers target vaccines for a new market: pregnant women
Tesaro's ovarian cancer drug lengthens survival time in late-stage trial